Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 18, 2019 (7 years ago)

Neostigmine Methylsulfate

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations that can result in a lack of sterility assurance.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Neostigmine Methylsulfate, 5mg/5mL (1mg/mL), 5mL Single Dose Syringe, Rx only, Premier Pharmacy Labs, 8265 Commercial Way, Weeki Wachee, FL 34613, NDC: 69623-234-15, barcode 5 69623 23415 0.

Affected NDC 69623-0234-15

Compare with the code on your package — it is the most precise check available.

Drug: Neostigmine

Recalling firm
Premier Pharmacy Labs Inc
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1422-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Neostigmine recalls

See all
Class II · Moderate risk

neostigmine 5 mg/5mL

Lack of assurance of sterility. Validation data for decontamination cycles is lacking.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. D-0982-2023

Other recalls by Premier Pharmacy Labs Inc

All 2019 recalls
Class II · Moderate risk

SUCCINYLcholine Chloride

Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations that can result in a lack of sterility assurance.

Terminated Sterility / contamination Premier Pharmacy Labs Inc D-1428-2019
Class II · Moderate risk

SUCCINYLcholine Chloride

Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations that can result in a lack of sterility assurance.

Terminated Sterility / contamination Premier Pharmacy Labs Inc D-1427-2019
Class II · Moderate risk

Sodium Bicarbonate INJ 8.4%

Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations that can result in a lack of sterility assurance.

Terminated Sterility / contamination Premier Pharmacy Labs Inc D-1426-2019
Class II · Moderate risk

Riboflavin 5-Phosphate Sodium Ophthalmic Solution

Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations that can result in a lack of sterility assurance.

Terminated Sterility / contamination Premier Pharmacy Labs Inc D-1425-2019